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Autoregulation is a control mechanism common to 
several proteins of the steroid/thyroid hormone re- 
ceptor superfamily. In this work the effect of andro- 
gens and antiandrogens on the expression of the 
human androgen receptor (hAR) in prostate and 
breast cancer cell lines was studied. Northern blot 
analysis revealed a decrease in hAR steady state 
RNA levels in LNCaP cells by 3.3 nht of the synthetic 
androgen mibolerone. Maximal down-regulation of 
hAR RNA to 30% of control levels occurred 48 h 
after hormone addition. T47D breast cancer cells 
showed a similar effect with mibolerone, while hAR 
expression in normal skin fibroblasts did not re- 
spond to androgen treatment. As shown by nuclease 
Sl analysis, hAR transcripts initiate at three principal 
start sites, all of which are equally sensitive to an- 
drogen. Steroidal as well as nonsteroidal antiandro- 
gens were capable of partially antagonizing andro- 
gen-mediated hAR RNA down-regulation in LNCaP 
and T47D cells, while not exerting a significant effect 
when administered alone. While hAR RNA stability 
was increased by hormone, nuclear run-on analysis 
revealed a 4-fold reduction of hAR gene transcrip 
tion 98 h after androgen treatment. Although de- 
creased hAR RNA levels did not coincide with a 
parallel decrease in AR protein levels, analysis of 
androgen-inducible reporter constructs demon- 
strated that prolonged androgen administration to 
ceils results in a progressively impaired sensitivity 
of the intracellular androgen response mechanism. 
These results show that prolonged androgen expo- 
sure leads, besides its effect on hAR RNA levels, to 
functional inactivation of the AR. Thus, in viva, post- 
translational control of AR activity appears to be a 
novel mechanism of negative autoregulation of an- 
drogen effects on gene expression. (Molecular En- 
docrinology 7: 924-938 1993) 
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INTRODUCTION 
The androgen receptor (AR) is a member of the steroid 
and thyroid hormone receptor superfamily of ligand- 
inducible transcription factors (for review see Ref. 1). 
Cotransfection experiments of AR cDNA with a reporter 
construct have shown that the AR mediates androgen- 
regulated gene transcription (2, 3). By analogy with 
other steroid hormone receptors it is assumed that a 
complex between hormone and receptor is formed 
within the cell. A conformational change of this complex 
enables specific binding to recognition sequences near 
the promoter of the target gene to be activated. Mod- 
ulation of the rate of transcription initiation is the ulti- 
mate result (for review see Refs. 4-6). 
AR cDNAs have been cloned from various species 
(7-l 0). Comparative sequence analysis has revealed 
the typical domain structure (reviewed in Ref. 1 l), which 
is highly conserved among the members of the steroid 
hormone receptor family (4). Deletion mutagenesis has 
identified three functionally important regions: an amino 
terminal segment involved in transcriptional activation, 
a cysteine-rich DNA-binding domain, and a carboxy- 
terminal hormone-binding domain. A nuclear transloca- 
tion signal homologous to that found in the SV40 large 
T antigen was recognized within the hinge region be- 
tween the DNA- and steroid-binding domains (12). 
The promoter regions of the human AR (hAR) and 
rat AR (rAR) genes lack typical TATA and CAAT se- 
quence motifs but include a GC-rich region and contain 
putative Spl binding sites characteristic of house- 
keeping promoters. Sl nuclease protection analyses 
have demonstrated two major transcription initiation 
sites separated by few nucleotides, approximately 1 .l 
kilobases (kb) upstream of the initiator methionine of 
the AR gene (13, 14). 
Expression and regulation of the hAR and rAR genes 
have been investigated in cell lines and in animals. 
Significant expression of hAR RNA was detected in 
malignant breast (13) liver (15) and prostate ceil lines 
(16) as well as in primary genital skin fibroblasts (13). 
In the rat ventral prostate (15, 17, 18) and in the human 
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prostate cancer cell line LNCaP, expression of AR RNA 
is regulated by androgens (19, 20). Androgen with- 
drawal increases and androgen administration de- 
creases AR steady state RNA as assayed by Northern 
hybridization. In addition, in the human hepatoma cell 
line HepG2 and in the human mammary cancer cell line 
MFM-223 autologous down-regulation of AR RNA co- 
incides with decreased AR protein levels (15,21). These 
observations have led to the concept of negative auto- 
regulation of AR expression in rat and human tissues 
analogous to that observed for other steroid hormone 
receptors (22-28). However, this hypothesis has re- 
mained controversial, since other studies, employing 
ligand-binding assays, have demonstrated positive au- 
toregulation of AR protein levels in genital skin fibro- 
blasts (29, 30). In contrast, by in situ hybridization and 
immunocytochemistry, Takeda et al. (18) have demon- 
strated up-regulation of both AR RNA and AR protein 
in the prostate of androgen-treated rats and mice. An 
even more complicated scenario has emerged from 
studies in LNCaP cells where androgen-dependent 
down-regulation of AR RNA appears to coincide with a 
transient P-fold up-regulation of the AR protein (19). On 
the other hand, we reported recently that rapid protein 
synthesis-independent androgen induction of prostate- 
specific antigen (PSA) gene transcription in LNCaP cells 
takes a transient course, thereby pointing to a negative 
regulation of the androgen response pathway after 
long-term hormone administration (31). 
In this study we have thoroughly reevaluated the 
effects of androgen on AR steady state RNA and 
protein levels in LNCaP cells. Moreover, we have per- 
formed experiments to study the hormonal regulation 
of AR expression with respect to hAR RNA metabolism, 
promoter usage, and transcriptional activity of the hAR 
gene, as well as subcellular localization and functional 
activity of the AR protein. We demonstrate that AR 
transcription from all mRNA initiation sites is negatively 
regulated by androgens in human prostate and breast 
cancer cell lines but not in normal human fibroblasts. 
Although hAR RNA down-regulation apparently does 
not coincide with reduced receptor protein levels or 
altered subcellular localization, androgen administration 
leads to functional desensitization of the intracellular 
hormone response mechanism in LNCaP and T47D 
cells as judged by the ability to activate androgen- 
responsive reporter gene constructs. Thus functional 
inactivation provides a novel mechanism of negative 
autoregulation of androgen action on gene expression. 
RESULTS 
Effect of Androgen on AR Steady State RNA Levels 
To document the effect of androgens on hAR steady 
state RNA levels, the AR-containing cell line LNCaP 
(32) was treated for increasing periods of time with 3.3 
nM of the nonmetabolizable synthetic androgen mibol- 
erone (MIB) (33). RNA was analyzed on Northern blots 
probed with an hAR cDNA fragment. In LNCaP cells 
three major hAR RNAs of 11 kb, 8 kb, and 4.7 kb are 
detectable (Fig. 1 A). While the 11 -kb RNA represents 
the full-length transcript containing all exons, the 8-kb 
RNA originates from the use of an alternative splice site 
thus leading to the loss of 3 kb 3’untranslated se- 
quences (14). The identity of the 4.7-kb RNA remains 
uncertain. It was proposed that the 4.7-kb signal de 
rives from unspecific hybridization of 28s ribosomal 
RNA (17). As shown in Fig. 1 A, all three hAR transcripts 
continuously decrease with similar kinetics within 120 
h of hormone incubation. Since equal amounts of total 
RNA were loaded on each gel lane, unspecific cross- 
hybridization to 28s ribosomal RNA does not explain 
the disappearance of the 4.7-kb transcript after MIB 
treatment. Therefore the 4.7-kb RNA probably repre- 
sents a degradation product of the high molecular 
weight forms of hAR RNAs (14). However, this mRNA 
is still considerably longer than the protein coding part 
of the hAR cDNA [2730 base pairs (bp)], and therefore 
we cannot rule out a possible coding capacity of the 
4.7-kb RNA. 
Down-regulation of hAR RNA by MIB in LNCaP cells 
is down to 30% of control levels and is maximal after 
48 h as compared to RNA levels simultaneously deter- 
mined in the absence of MIB (Fig. 18). Thus hAR RNA 
down-regulation in LNCaP cells is a delayed hormone 
effect. The RNA level of the gene for the glycolysis 
enzyme glyceraldehyde phosphate dehydrogenase 
(GAPDH) is not significantly influenced by MIS, and the 
corresponding RNA can thus be used to correct for 
unequal loading of RNA per lane. 
To explore whether autologous down-regulation of 
the hAR gene is a phenomenon restricted to trans- 
formed LNCaP cells only, other normal and transformed 
human cells were analyzed. Normal genital skin fibro- 
blasts (GSF) derived from infant foreskin as well as the 
human breast cancer cell line T47D express substantial 
amounts of hAR RNA (Fig. 1 C). In T47D cells and GSF 
the major RNA species of 11 kb and 8 kb are detectable. 
The Northern blot in Fig. 1C moreover shows that, 
while hAR expression in T47D cells was equally sensi- 
tive to MIB, normal GSF showed no effect of MIB on 
hAR steady state RNA (Fig. 1C). The kinetics of hAR 
down-regulation in T47D cells were similar to the kinet- 
ics observed in LNCaP cells (data not shown). 
AR RNAs Starting from Different Transcription 
Initiation Sites are Equally Sensitive to Androgen 
Expression of the hAR gene uses a common promoter 
in diverse human tissues. Although, according to earlier 
reports (13, 14) the heterogeneity of transcription ini- 
tiation described for a number of genes lacking canon- 
ical CAAT and TATA box sequences is also a property 
of the hAR gene, two major transcription initiation sites 
separated by few nucleotides have been recognized. 
Using a uniformly labeled single-stranded probe derived 
from the hAR upstream region, we have analyzed the 
hormone sensitivity of the different hAR RNA initiation 
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Fig. 1. Northem Blot Analysis of Total RNA of LNCaP, T47D, and GSF Cells after Treatment with the Synthetic Andmgen MIB 
A, LNCaP cells were cultivated in the presence (+) or absence (-) of 3.3 nM MIB for various periods from O-120 h. RNA was 
extracted and analyzed on Northem blots (20 Mg/lane) hybridized with an hAR EcoRI/Pstl cDNA probe labeled by random priming. 
Subsequently the probe was washed off, and the filter was rehybridized with a probe for the housekeeping enzyme GAPDH (62). 
B, The autoradiirams were scanned densitometrically, and the results of hAf? hybridization relative to GAPDH are shown 
schemaWIly in a block diagram. C, T47D cells and GSFs were treated with MIB for 96 h. Total cellular RNA was isolated, and 
filters were hybridized with the hAR o&e as in A. The ethidium bromide-stained gels before transfer are shown to document equal 
RNA loading per lane. 
sites in a nuclease Sl protection assay. This seemed 
reasonable since the incomplete disappearance of hAR 
RNA even after prolonged hormone administration 
could reflect a differential effect of MIB on individual 
RNA start sites. We have recently observed differential 
effects of MIB on the promoter usage of the c-myc 
protooncogene in LNCaP cells (34). 
Figure 2A confirms the results of previous reports 
showing that hAR gene expression in several cell types 
uses two principal mRNA initiation sites located 1115 
and 1126 nucleotides in front of the ATG translation 
initiation codon. The upstream and downstream start 
sites are referred to as I1 and 12, respectively. In un- 
treated LNCaP and T47D cells the relative usage of 
sites I1 :I2 is 1.51 as determined by densitometric scan- 
ning of the corresponding bands (data not shown). In 
addition to the I1 and I2 bands, a third, smaller band, 
13, is found which comprises 20% of the total hAR RNA. 
Since I3 was not recognized in previous reports, we 
have mapped this start site relative to a sequencing 
reaction of this region starting from primer hAR 5. It 
turned out to be 4-6 nucleotides downstream of I2 (Fig. 
2A). As can be gathered from Fig. 28, the transcripts 
initiating from the three mRNA start sites are equally 
sensitive to autdogous down-regulation by MIB in 
LNCaP and T47D cells but again not in GSF. Note that 
the internal ratio of start site usage does not change 
upon hormone addition (Fig. 28). These results show 
that II, 12, and I3 are subject to a common regulatory 
mechanism by androgens. 
Effect of Antiandrogens on AR RNA Expmasion 
Transduction of hormonal signals into the nucleus lead- 
ing to modulation of gene expression is known to 
involve the hormone receptor protein. To evaluate the 
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Fig. 2. Androgen Sensitivity of AR RNA Start Sites 
A, Mapping of hAR RNA initiation sites by nuclease Sl 
protection assay with an antisense DNA probe derived from 
the hAR promoter region run in parallel with a sequencing 
reaction starting from primer hAR5. RNA derived from initiation 
site 1 (II) protected fragments of 134-137 bases, from I2 
fragments of 126-127 bases, and from I3 fragments of 121- 
122 bases. B, Several of the RNAs described in Fig. 1 were 
subjected to nuclease Sl analysis. P, Labeled DNA probe; M, 
molecular weight standard; t, yeast tRNA. 
possible participation of the AR protein in hAR RNA 
down-regulation by MIB, we tried to antagonize the 
androgen effect by the simultaneous addition of AR 
blocking agents (antiandrogens). The steroidal antian- 
drogen cyproterone acetate (CA) as well as the nonste- 
roidal antiandrogen hydroxy flutamide (Flu-OH) were 
recently shown to effectively prevent the inhibitory ac- 
tion of MIB on proliferation and c-myc expression in 
LNCaP cells (34, 35) while not exerting any effect when 
administered alone. Due to the relatively low affinity of 
antiandrogens for the AR a several hundredfold molar 
excess over the androgen is required for effective block- 
age of androgen action (36). 
Figure 3 again shows autologous down-regulation of 
hAR RNA by MIB. However, the simultaneous presence 
of CA or Flu-OH for 96 h partially abolishes the effect 
of MIB on all species of hAR steady state RNA. Antian- 
drogens alone have no significant effect on hAR RNA 
expression in LNCaP cells. Identical results were ob- 
tained for hAR regulation by antiandrogens in T47D 
cells (data not shown). 
Quarmby et a/. (17) recently reported drastic hAR 
down-regulation in LNCaP cells in response to the 
antiandrogen CA. To substantiate our contradictory 
findings, we have studied the effect of CA on hAR 
expression under more rigorous conditions. After down- 
regulation of hAR RNA by treating LNCaP cells for 72 
h with MIB, the culture medium was renewed, an 
appropriate amount of CA but no MIB was added, and 
cells were harvested for RNA preparation after different 
periods. As shown in Fig. 3C, CA is not in a position to 
maintain the low level of hAR expression induced by 
MIB pretreatment for 72 h. In contrast the presence of 
CA alone allows for the restoration of hAR RNA levels 
prevailing in untreated control cells. The kinetics of this 
reversion effect are similar to those obtained for autol- 
ogous hAR down-regulation by MIB. Only 24-48 h after 
the addition of CA, pretreatment levels of hAR RNA are 
achieved. These results clearly demonstrate that hAR 
down-regulation in our stock of LNCaP cells is strongly 
antagonized by antiandrogens and thus in principle 
reversible. We conclude that the AR protein is involved 
in the process of autologous hAR regulation. 
AR RNA Down-Regulation by MIB Occurs at the 
Level of Transcription initiation 
The AR is presumed to act as a transcription initiation 
modulator, but several in viva studies of known andro- 
gen target genes have suggested that andrcgens pri- 
marily control RNA stability (37, 38). We therefore 
measured the effect of MIB on hAR RNA half-life. 
LNCaP control cells and cells incubated with MIB were 
treated with the RNA synthesis inhibitor actinomycin D 
(5 pg/ml) for different periods from O-24 h. As shown 
in Fig. 4A, the half-life of the hAR RNA in untreated 
LNCaP cells is 3.8 h. Preinduction of cells with MIB for 
72 h increased hAR RNA half-life to 6.4 h. Notably, an 
accelerated turnover of hAR RNA in the presence of 
MIB was not detectable in LNCaP cells (Fig. 4A), making 
a posttranscriptional mechanism of hAR RNA down- 
regulation in LNCaP cells unlikely. 
The fact that the AR protein is apparently involved in 
hAR RNA down-regulation without decreasing hAR 
RNA half-life prompted us to investigate the effect of 
androgens on hAR transcription. Autologous down- 
regulation of the RNAs of various steroid hormone 
receptors was shown to occur at the level of transcrip 
tion initiation (23, 26, 28). Run-on analysis was per- 
formed in nuclei isolated from cells treated with MIB 
and/or CA for 96 h. Nuclear transcripts were hybridized 
to strand-specific hAR cDNA probes. Probes for the 
PSA gene and the gene encoding phosphoglycerate 
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Fig. 3. Northem Blot Analysis of RNA of LNCaP Cells Treated with the Synthetic Androgen MIB and the Antiandrogeh CA 
A, LNCaP cells were maintained in the presence (+) or absence (-) of 3.3 nM MIB and 1.8 MM CA or 2.6 PM Flu-OH. RNA was 
isolated and analyzed on Northern blots (20 pg/lane) with the hAR probe. Filters were reprobed with GAPDH to correct for unequal 
loading of RNA per lane. B, Densitometric analysis of the blot presented in A. C, Effect of antiandropen oh hAR RNA levels after 
preincubation with MIB. LNCaP cells were maintained in the presence of 3.3 nM MIB. After 72 h the medium was removed, and 
1.8 PM of CA but no MIB were added. RNA was isolated after diierent Periods between 0 and 72 h and Probed on Northern blots 
with the hAR probe. 
kinase (PGK) were used as controls. As shown in Fig. 
48, significant hAR transcription in LNCaP cells is only 
observed on the coding strand. Treatment with MIB but 
not with the antiandrogen CA suppresses hAR tran- 
scription by 75% compared to untreated controls (scan- 
ning data not shown). Combined administration of MIB 
+ CA largely prevents down-regulation of hAR tran- 
scription. The transcription rate for the PSA and PGK 
genes after 96 h is influenced by neither hormone 
treatment. 
Effect of Androgen on AR Protein Expression 
The results presented above demonstrate that andro- 
gens negatively regulate hAR RNA expression at the 
level of transcription initiation. Autologous down-regu- 
lation of progesterone and estrogen receptor RNAs 
was reported to correspond to reduced receptor protein 
levels (24-26,28). In the human cancer cell lines HepG2 
and MFM-233 as well as in the rat ventral prostate AR 
RNA down-regulation also leads to a decrease of AR 
protein (15, 17, 21). In contrast Krongrad et al. (19) 
recently reported slightly increased AR protein levels 
early after androgen administration to LNCaP cells. 
To see whether or not changes in hAR RNA result in 
altered protein expression under our culture conditions, 
total cellular proteins of LNCaP cells, T47D cells, and 
GSF were probed on immunoblots with the monoctonal 
antibody F39.4.1 (39) directed against the hAR. In 
LNCaP cells the antibody recognized two proteins mi- 
grating with an apparent mol wt of about 11OK as 
expected for the hAR (40) (Fig. 5). In T47D cells and in 
GSF the amount of receptor protein was obviously too 
low to be detected by this antibody. After 96 h of 
androgen treatment, i.e. at a time point at which hAR 
RNA down-regulation is maximal, the same amount of 
AR protein was detectable in androgen-treated vs. con- 
trol samples of LNCaP cells. However, both protein 
bands migrated with a slightly slower mobility, sug- 
gesting a posttranslational modification. This result was 
confirmed in two independent experiments. 
In order to be able to directly follow the intracellular 
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Fig. 4. Posttranscriptional and Transcriptional Regulation of the hAR Gene by MIB 
A, Effect of MIB on hAR RNA half-life. Untreated LNCaP cells and cells treated with MIB for 72 h were incubated for various 
periods from O-24 h with actinomycin D (5 rg/ml), and RNA was isolated and subjected to Northern analysis by hybridization with 
an hAR cDNA probe. Autoradiograms were scanned, and hAR half-lives were calculated by regression analysis of absolute MR 
RNA levels at each time point after actinomycin-D treatment. The ethidium bromide-stained gels before transfer are shown below 
the autoradiograms. B, Transcriptional regulation of the hAR gene by androgen and antiandrogen in LNCaP cells. Ptasmids 
containing double-stranded and single-stranded DNA probes were transferred to nylon membranes by slot blot and hybridized with 
nuclear run-on RNA (10’ cpm/3 ml hybridization buffer) from cells treated without or with MIB and/or CA for 96 h. Probes detecting 
sense RNA are marked by +, those detecting antisense RNA by -. 
LNCaP T47D GSF 
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F@ 5. Western Blot Analysis of AR Protein Expression 
LNCaP cells, T47D cells, and GSFs were cultivated either 
in the presence (+) or absence (-) of 3.3 nhi MIB for 96 h, and 
total cellular proteins were isolated. Proteins were separated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
and immunological detection was performed using the mono- 
ckmal antibody F39.4.1 as described in Materials and Methods. 
AR protein expression in T47D cells and in GSF was too low 
to be detected by this antibody. 
dynamics of the AR, we carried out immunocytochem- 
ical analyses of AR protein expression in LNCaP cells 
treated with androgen for different periods. LNCaP 
cells, when maintained in the presence of 10% unmod- 
ified fetal calf serum (FCS), which contains approxi- 
mately 0.1 nM testosterone and androstendione (41) 
[i.e. at least lOO-fold less than normal male sera (42)], 
showed predominantly nuclear staining of the AR (Fig. 
6B). While a recombinant AR expressed in COS celb 
was reported to be enriched in the perinuclear region 
of the cytoplasm before hormone addition (12, 43), 
nuclear staining in LNCaP cells was even preserved 
after maintenance in serum-free medium for 48 h (Fig. 
6A). Addition of physiological amounts of androgen for 
various periods (3-96 h) resulted in neither a qualitative 
nor a significant quantitative change in AR staining (Fig. 
6, C-F). In the AR-negative prostate cancer cell line 
DU145 (44) only slight background staining was ob- 
served (Fig. 6H), as was the case with LNCaP control 
slides not incubated with the specific primary antibody 
(Fig. 6G). These results confirm and extend those of 
Krongrad et al. (19), demonstrating that, at least in 
LNCaP cells, hAR RNA down-regulation does not nec- 
essarily coincide with reduced protein levels or altered 
subcellular localization. 
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Fig. 6. lmmunocytochemical Analysis of AR Protein Expression 
LNCaP cells were maintained either in serum-free medium (A) or in medium containing 3.3 nM MIB, cultivated for 0 h (B), 3 h (C), 
12 h (D), 48 h (E), and 96 h (F), fixed, and processed for indirect immunofluorescent labeling using the monoclonal antibody F39.4.1. 
The AR-negative prostate cancer cell line DU145 (H) and a sample of LNCaP cells not incubated with the specific primary antibody 
are used as controls (G) 
Functional Inactivation of the AR after Prolonged 
Hormone Administration 
In previous reports we demonstrated that MIB rapidly 
and transiently increases PSA gene transcription in 
LNCaP cells (31, 34). Maximal induction occurred after 
3 h and slowly declined toward pretreatment levels 
from 48 to 96 h. From these kinetics we concluded that 
androgen-dependent PSA induction is a direct hormone 
effect involving the binding of the AR to an element 
present in the PSA promoter, closely resembling the 
consensus sequence for hormone response elements 
(31). Moreover, we speculated that the transient char- 
acter of PSA induction might be due to inactivation of 
the intracellular hormone response mechanism. With 
regard to the parallel kinetics of PSA inducibility and 
hAR RNA levels, it seems intuitively logical to consider 
a numerical reduction of AR molecules per cell as a 
consequence of hAR RNA down-regulation being re- 
sponsible for this effect. However, the immunoblotting 
data presented above point to a functional inactivation 
of the AR after prolonged hormone administration in 
the presence of stable amounts of receptor proteins. 
To test this hypothesis, we have cloned the natural 
PSA promoter in front of a promoterless chloramphen- 
icol acetyltransferase (CAT) reporter plasmid and as- 
sayed for inducibility under various conditions of andro- 
gen treatment. The construct PSACAT61 was trans- 
fected by electroporation into LNCaP and T47D cells 
pretreated with MIB for increasing periods of time. 
Immediately after transfection duplicate dishes either 
did or did not receive 3.3 nM MIB for 48 h. In cells not 
preincubated with MIB, a 7- to g-fold increase of CAT 
expression is found upon androgen stimulation (Fig. 
7A), showing that the PSA promoter contains an andro- 
gen-inducible enhancer. However, with increased times 
of MIB preincubation in the range of 24-96 h, androgen 
inducibility of PSACAT61 in both cell lines decreases 
as compared to control levels simultaneously deter- 
mined in the absence of hormone (Fig. 7A). CAT induc- 
tion showed some variability during the first 48 h of 
hormone pretreatment but was consistently more than 
5-fold reduced after 96 h. 
Since the PSA promoter fragment used for construc- 
tion of PSACAT61 has an approximate length of 5 kb, 
we could not rule out the possibility that numerical or 
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Fig. 7. Effect of MIB Pretreatment on Androgen lndudbility of PSACAT61 (A) and pG29GtkCAT (B) in LNCaP and T47D Cells 
Duplicate cultures of cells pretreated with 3.3 nM MIB for increasing periods from O-96 h were transfected with 2.5 ag of the 
respective plasmids and either stimulated or not by the addition of androgen for 46 h. Protein extracts were prepared and assayed 
for CAT activity. TLC plates were autoradiographed, and autoradiograrns were scanned. Scanning data are presented in a block 
diagram. The factor of CAT induction was calculated as CAT activity in the presence of hormone divided by CAT activity without 
functional reduction of factors other than the AR is 
responsible for the self-limitation of androgen action on 
PSA transcription. We therefore performed control ex- 
periments with the plasmid G29GtkCAT which contains 
as sole androgen sensitive regulatory sequences two 
glucocorticoid/progesterone response elements 
spaced by 29 nucleotides directly in front of a thymidine 
kinase (tk) promoter-driven CAT construct (45). Again, 
in both cell lines, LNCaP and T47Q progressively re- 
duced androgen inducibility was detectable depending 
on the duration of MIB pretreatment (Fig 78). These 
results establish that, in vim, prolonged androgen ad- 
ministration results in self-limitation of androgende- 
pendent &ins-activation of androgen-sensitive pro- 
moters without any change in AR protein levels. 
DISCUSSION 
The phenomenon of negative autoregulation of the 
expression of genes encoding members of the steroid 
hormone receptor superfamily has previously been 
demonstrated for the estradiol receptor (26, 27) the 
progesterone receptor (24,25, 28) and the glucocorti- 
coid receptor (GR) (23, 46, 47). In this study we have 
analyzed in detail the hormonal regulation of the hAR 
with respect to promoter usage, RNA stability, rate of 
transcription, and trans-activating function. 
Androgen Regulation of hAR RNA Expression 
The mechanisms involved in autoregulation of other 
steroid receptor genes are diverse. While autologous 
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down-regulation of the progesterone receptor, the es- 
tradiol receptor, and the GR genes occurs at the level 
of transcription initiation in some cell types (23,26,28), 
the contribution of posttranscriptional mechanisms has 
been demonstrated in others (27). Negative autoregu- 
latiin of the hAR gene in homogeneous cultures of 
human prostate cancer cells (LNCaP) is primarily a 
consequence of reduced transcriptional initiation at all 
mRNA start sites. In view of available sequence data, 
this finding is particularly interesting. Within 500 bp 
upstream from the heterogeneous transcription initia- 
tion sites the promoter region of the rAR gene contains 
four repeats of the DNA-binding consensus sequence 
for steroid hormone receptors [hormone response ele- 
ment (HRE)] homologous to those found in other an- 
drogen-regulated genes (49). Given the high homology 
of the hAR and the rAR genes, the presence of HREs 
in the hAR gene promoter is possible. Unfortunately the 
published sequence of the hAR promoter region (13) 
does not extend to the region containing clustered 
HREs in the rat homolog, and a sequence comparison 
is thus impossible at present. Whether negative auto- 
regulation of hAR gene transcription is mediated by 
HREs, as is hormone-dependent rrans-activation (4) 
remains to be elucidated. 
On the other hand, trans-repression of the gene 
encoding the transcription factor Fos is fundamentally 
different from Fos-mediated trans-activation. The c-foe 
gene is subject to autorepression (50) but the target 
site is not an APl binding motif but the serum response 
element (SRE) (51-53). Since repression via the SRE 
requires an intact Fos leucine repeat but no functional 
DNA-binding site (52) Fos is presumed to interact with 
another protein and inhibit transcription by competing 
for a factor needed for activation of the SRE. Trans- 
repression of the collagenase I gene by the GR has 
also been shown to be independent of receptor DNA 
binding. In this case, &ens-repression is mediated by 
direct protein-protein interaction between the DNA- 
binding domain of the GR and the DNA-binding region 
of a Jun monomer (54). Thus trans-repression by the 
AR may also differ from frans-activation in that it might 
be independent of HRE binding but involve interaction 
with another tissue-specific protein which is probably 
lacking in genital skin fibroblasts. 
Data in favor of this model are provided by the 
analysis of antiandrogen action on hAR expression. 
The effects of antiandrogens on gene expression in 
LNCaP cells are particularly interesting, since a point 
mutation in the steroid-binding domain of the LNCaP 
cell hAR gene results in an altered hormone-binding 
specificity (55). Specifically, this mutation was shown 
to cause both increased receptor binding of CA com- 
pared to the wild type receptor and trans-activation of 
a reporter construct by CA via the mutated receptor 
(56,57). 
During recent years we have studied regulation by 
androgens and antiandrogens of three other genes in 
LNCaP cells. We demonstrated rapid transcriptional 
induction of kallikrein-like genes encoding PSA and 
human glandular kallikrein-1 (31) and delayed suppres- 
sion of c-myc oncogene transcrfption in LNCaP cells by 
MIB (34). While antiandrogens prevented the androgen 
effect on c-myc transcription, CA acts as an androgen 
agonist on kallikrein gene transcription (31) and con- 
sequently fails to antagonize androgen induction. Thus 
antiandrogens act differentially on androgen-regulated 
gene transcription in LNCaP cells. 
As in the case of c-myc transcriptii, CA is now 
shown also to antagonize the effect of MIB on hAR 
gene transcription and thus to behave as a classical 
antiandrogen, as does Flu-OH. This finding cannot be 
easily explained by the point mutation residing in the 
hAR gene of LNCaP cells. Since the wild type AR of 
T47D cells also mediates androgen-antagonistic activity 
of CA on hAR gene expression (data not shown), it 
appears that the mutated LNCaP AR behaves normally 
in transmitting CA signals on c-myc and hAR gene 
expression. 
Androgen regulation of c-myc and hAR gene tran- 
scription has several features in common, which distin- 
guishes it from kallikrein gene regulation: 1) c-myc and 
hAR genes are negatively regulated by androgens, 
whereas kallikrein genes are positively regulated; and 
2) while kallikrein gene induction is a rapid event taking 
less than 3 h until maximal induction has occurred, c- 
myc and hAR suppression is slow (>48 h). These 
differences may provide the basis for the differential 
effect of CA on androgen-regulated genes within one 
cell type. 
Although the number of genes investigated is limited, 
it appears from our studies that CA antagonizes andro- 
gen effects in LNCaP cells when slow negative regula- 
tion is executed. The pathways involved in this type of 
regulation are expected to include additional, still uni- 
dentified mechanisms which, as a net result, mediate 
androgen-antagonistic activity of CA. In contrast, rapid 
positive regulation, as in the case of kallikrein genes, 
appears to be a direct hormone effect with a significant 
penetrance of the receptor point mutation leading to 
androgen-agonistic activity of CA. According to the 
model presented above, in LNCaP cells, the alteration 
of AR conformation induced by CA may be appropriate 
to allow binding to HREs and trans-activation but may 
be insufficient to mediate interaction with other reguls 
tory proteins necessary for Vans-repression. 
Androgen Regulation of hAR Protein Expression 
Direct action of androgen analogs on the transcription 
of the androgen-regulated PSA gene has been shown 
to be mediated via the HRE homologous sequence 
residing 150 bp upstream of the RNA initiation site (58). 
Although androgen analogs are metabolically stable 
over prolonged periods (59) PSA induction in LNCaP 
cells is transient (48-96 h) (31, 34) indicatfng that 
androgen action is attenuated somewhere downstream 
of the ligand but upstream of the target sequence. 
From the parallel kinetics of hAR RNA down-regula- 
tion and PSA inducibility one tentatively could infer that 
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reduced RNA levels might result in decreased protein 
levels, thus accomplishing transience of PSA induction. 
As demonstrated by immunoblot analysis, this model, 
which may hold true for most steroid receptors in other 
cell systems (15, 21, 24-26, 28), proved too simple in 
the case of the AR in LNCaP cells. Maximal down- 
regulation of hAR RNA after exposure to androgen for 
96 h remains without a measurable effect on AR protein 
levels in LNCaP cells (Fig. 5). It thus appears that the 
principal aim of hAR gene regulation in LNCaP cells is 
to maintain constant AR protein levels over prolonged 
periods of androgen exposure. Since androgen admin- 
istration is known to result in increased stability of the 
AR protein (43) the cell apparently has to activate a 
complex pattern of regulatory mechanisms including 
transcriptional shut-off of the hAR gene as well as 
posttranscriptional stabilization of hAR RNA (Fig. 4A) in 
order to keep AR protein levels constant. 
The question remains, however, why, despite the 
presence of high amounts of receptor molecules as well 
as receptor ligand, the transcriptional inducibility of the 
androgen-regulated PSA gene is transient. The results 
presented in this study provide a key to understanding 
this process by the demonstration that, in viva, down- 
regulation of hAR RNA but not AR protein coincides 
with reduced inducibility of a reporter construct under 
the control of PSA regulatory sequences (Fig. 7A). 
Interestingly, a minimal promoter containing only two 
HREs is also subject to self-limited inducibility depend- 
ing on the duration of hormone pretreatment (Fig. 7B), 
demonstrating that the AR protein is functionally im- 
paired in LNCaP and T47D cells treated with hormone 
for prolonged periods. A similar observation was very 
recently reported by Hackenberg et al. (21) in another 
human breast cancer cell line. Thus posttranslational 
control may be the actual mechanism of self-limitation 
of androgen effects on gene expression. 
Within the particular signal transduction pathway ac- 
tivated by steroid hormones (reviewed in Refs. 4, 6), 
several explanations for the self-limitation of receptor- 
mediated effects on gene expression are conceivable. 
Upon passively entering the cell, the hormone binds to 
its homologous receptor. As a consequence of hor- 
mone binding the receptor dissociates from heat shock 
proteins, a process which enables homodimerization, 
heterooliaomerization with other proteins, and binding 
to target&!quences on the DNA, eventually resulting in 
tfaans-activation or tfans-repression of responsive pro- 
moters. Constant levels of receptor proteins and ligand 
provided posttranslational autoregulation of receptor 
activity is theoretically possible at several levels: nuclear 
translocation, heat shock protein interaction, receptor 
dimerization, oligomerization with other proteins, DNA 
binding, and transactivation potential. While it has al- 
ready been shown that phosphorylation of the AR in 
response to hormone administration is a potential form 
of posttranslational modification (43, 60), our studies 
rule out the model that this modification might alter the 
subcellular localization of the AR, which in turn could 
lead to nuclear exclusion and consequent impairment 
of trans-activating function. 
In conclusion, this study uncovers a novel level of AR 
regulation and indicates that a complex pattern of tran- 
scriptional and posttranscriptional mechanisms oper- 
ates in LNCaP cells to bring about fine tuning of the 
homeostasis of receptor-mediated androgen effects on 
gene expression. 
MATERIALS AND METHODS 
Cell Culture and Hormones 
The human prostate cancer cell line LNCaP (32) was from the 
Human Cancer Cell Laboratory, Sloan Kettering Institute for 
Cancer Research (Rye, NY). LNCaP cells between passages 
70 and 80 were used for the experiments described. LNCaP 
cells were maintained in RPM1 1840 as monolayers in the 
presence of 10% FCS and 2 mM glutamine as described (35). 
The human breast cancer cell line T47D (81) was kindly 
provided by Dr. R. Renkawitz (University of Giessen, Giesaen, 
Germany). T47D cells were cultivated in Dulbeccc’s modified 
Eagle’s medium containing 10% FCS and 2 mM glutamine. 
GSFs were isolated from primary cultures of human foreskin 
keratincqtes. Infant foreskins obtained by routine circumci- 
sion were freed from adjacent blood vessels and placed on a 
trypsin/EDTA solution (0.25% trypsin/0.05% EDTA) in PBS 
devoid of Ca” and Mg2+ at 4 C for 21 h. Cells were separated 
from the upper side of the dermis and filtered through sterile 
gauze into a 0.01% solution of soybean trypsin inhibitor in 
PBS. After centtifugation at 1000 rpm for 5 min, the cells were 
resuspended in serum-free keratinocyte medium (GIBCO, 
Grand Island, NY) containing 5 pg/liter epidermal growth fac- 
tor, 50 mg/liter bovine pituitary extract and gentamicin, and 
seeded into tissue culture flasks. Upon reaching approximately 
75% confluency, the medium was removed, and the cells were 
washed twice with Ca2+/Mg2+-free PBS and incubated in 2 ml 
trvbsin/EDTA solution (0.025% trvbsin/0.02% EDTA) for 2 min 
ai d. During that period the fibroblasts detach fir& as they 
are less adherent to the substratum than the keratinocytes. 
Cells were aspirated and suspended in Dulbeccu’s modified 
Eagle’s medium containing 10% FCS and 2 mM glutamine. 
For the preparation of seed stocks, cells were grown to 50- 
75% confluency before use. Hormones were added 48 h after 
seeding as ethanol solutions. Final concentrations of the hor- 
mones were 3.3 nM for the synthetic andrcgen MIB (Upjohn, 
Kalamazoo, Ml), 1.8 PM for the antiandrcgen CA (Schering 
AG, Berlin, Germany) and 2.8 PM for the antiandrcgen Flu-OH 
(Essex). Actinomycin D (Boehringer Mannheim, Mannheim, 
Germany) was used at a final concentration of 5 pg/ml. 
RNA Extraction and Northern Blot Analysis 
Standard protocols were followed as described elsewhere 
(35). Autoradidgrams were scanned in an LKB (Bromma, 
Sweden) Ultra&an XL Laser Densitometer. 
Hybridization Probes and Plasmids 
32P Labeling was performed with a random-primed labeling kit 
(Boehringer Mannheim) according to the recommendations of 
the supplier. The 450-bp EcoRI/Pstl cDNA fragment used as 
an hAR probe for Northern analyses was generated by pulym- 
erase chain reaction from reverse-transcribed total cellular 
RNA isolated from LNCaP cells. The probe covers sequences 
encoding parts of the homtcne-binding domain and the 3’- 
untranslated region. The probe for the housekeeping enzyme 
GAPDH was a synthetic single-stranded digonudectide (100 
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bases) derived from the published sequence (62) and was end- 
labeled with polynucleotide kinase. 
For the nuclear run-on transcription assays the plasmid 
pSVARo (kindly provided by J. Trapman, Erasmus University, 
Rotterdam, The Netherlands) was digested with HindIll and 
Pstl (positions 1850-3002 according to Ref. 63), and the 
resulting 1 .15-kb fragment was subcloned in both orientations 
into Ml 3 mp18 and mpl9 phages. The probe for PSA was an 
EcoRl cDNA fragment spanning the complete coding region 
for the mature PSA protein (64). The probe for the gene 
encoding PGK was a 1.8-kb cDNA subcloned in pBR 328 (65). 
The template for the AR probe used in the nuclease Sl 
protection assays was amplified from 1 pg genomic DNA from 
LNCaP cells by the polymerase chain reaction. The primer 
hAR3 corresponded to nucleotides -300 to -278 and the 
primer hAR5 to nucleotides 119-l 39 relative to 12 (numbered 
according to Ref. 13). The resulting 438-bp fragment, termed 
PAR1 , was cloned into Ml 3 mp18 (Ml 3PARl). 
The PSACAT61 plasmid used in DNA transfection assays 
was generated by inserting a genomic HindIll fragment con- 
taining the genuine PSA promoter in addition to 5 kb PSA 
upstream sequences into the promoterless CAT reporter plas- 
mid pBLCAT6 (generously provided by G. Schlitz, Deutsches 
Krebs-Forschungzentrum, Heidelberg, Germany). The andro- 
gen-inducible control plasmid G29GtkCAT contains two prc- 
gesterone/glucocorticoid response elements upstream from a 
herpes simplex virus tk promoter-driven CAT construct (45) 
and was kindly provided by R. Renkawitz. 
Sl Nuclease Protection Assay 
A single-stranded uniformly labeled DNA probe was prepared 
by primer extension of M13PARl in the presence of [&*P] 
deoxy-ATP and [a-32P]deoxy-CTP. The extended products 
were digested with the restriction endonuclease BssHII, and 
the labeled probe was separated from the Ml3 template on a 
5% denaturing polyacrylamide gel. The probe was detected 
by autoradiography and eluted with 0.5 M ammonium acetate, 
10 mM magnesium acetate, and 10 mM EDTA (pH 8.0) for 8 h 
at 37 C. Hybridization of labeled DNA fragments to total RNA 
was carried out using a modification of the method of Berk 
and Sharp (86). Hybridization mixtures of 20 ~1 containing 5 x 
10’ cpm of the labeled antisense probe, 30 pg (LNCaP) or 60 
Pg (T47D and GSF) RNA, 80% formamide, 400 mM NaCI, 40 
mM piperazin&,N’-bis(2ethanesulfonic acid), pH 6.5, and 1 
mM EDTA were denatured at 90 C for 5 min and immediately 
transferred to 52 C. After 15 h the hybridization was terminated 
by addition of 180 ~1 icecold buffer containing 250 mM NaCI. 
30 mM Na-acetate, pH 4.5, 2 mM Zn-acetate, 5% glycerol, and 
400 U nuclease Sl (Boehringer Mannheim). After incubating 
the samples at 42 C for 1 h, the reaction was stopped by the 
addition of 50 ~1 4 M ammonium actetate, 50 mM EDTA, and 
50 pg/ml yeast tRNA, and the nucleic acid was precipitated 
with ethanol. Protected DNA fragments were separated on 
7% polyacrylamide gels containing 7 M urea. Gels were dried 
and exposed to Fuji (Tokyo, Japan) X-ray films for 8-12 h 
between intensifying screens at -80 C. 
Nuclear Run-On Analysis 
Preparation of cell nuclei and hybridization were performed as 
de&Wed (34). Filters were exposed to Fuji X-ray films be- 
tween DuPont (New England Nuclear, Boston, MA) Lightning 
Plus intensifying screens for 3 days. 
Cellular proteins were isolated according to Sambrook et al. 
(67) and stored in aliquots at -80 C until use. Equal amounts 
of protein (80 ag/lane) were passed through a 4% stacking 
gel and separated in an 8% resolution gel. After elactropho- 
resis gels were blotted onto nylon membranes (Millipore, Bed- 
ford, MA; Immobilon-P) using an electroblot apparatus oper- 
ating at 35 mA for 12 h. Membranes were blocked by two 
sequential incubations in 5% low-fat powdered milk (dissolved 
in PBS) for 90 min each. Filters were incubated with a 1:lOO 
dilution of the hAR antibody F39.4.1 (39) (Monosan, Uden, The 
Netherlands) for 3 h at room temperature on a rocking platform 
and for an additional 8 h at 4 C without shaking. Unbound 
antibody was removed by five washes, 10 min each, in PBS/ 
0.1% Tween 20 at room temperature. Incubation with a per- 
oxidase-conjugated antimouse immunoglobulin G antibody 
was performed at room temperature for 2 h on a rocking table. 
After five washes in PBS/O.l% Tween 20, immunoreactive 
bands were visualized by incubation in 80 ml of a PBS solution 
containing 30 mg diaminobenzidine (Sigma, St. Louis, MO) 
and 30 ~1 H202. After achieving maximal band intensity filters 
were rinsed in distilled water and photographed. 
lmmunocytochemistry 
LNCaP cells were seeded onto glass cover slips in the absence 
or presence of FCS and/or 3.3 nM MIB. After different times 
cells were washed twice in PBS and fixed for 30 min at 4 C in 
2% paraformaldehyde. Cells were washed and incubated in 
PBS containing 0.01% saponine (Sigma) and 0.01% sodium 
azide for 15 min. Cells w&e incubated for 1 h at 37 C with a 
1 :lO dilution of the monoclinal antiiv F39.4.1 in PBS/ 
saponine, followed by three washes in bBS/saponine. The 
tetramethylrhodamine B isothiocyanate-labeled secondary an- 
timouse immunoglobulin G antibody was used at a 1:40 dilu- 
tion for 45 min at 37 C. After 2 washes in PBS/saponine and 
two washes in PBS alone, cover slips were prepared for 
fluorescent microscopy, and representative sections were 
photographed at a 400-fold magnification. 
DNA Transfection and Assay for CAT Activity 
DNA transfection was performed by electroporation using a 
Bio-Rad (Richmond, CA) Gene Pulser operating at 300 V (960 
microfarads). Cells were preincubated with 3.3 nM MIB for 
various periods (time points indicated in Fig. 7). After the 
preincubation period cell numbers were adjusted to 5 x lo6 
cells per sample suspended in 800 ~1 culture medium in an 
electroporation cuvette; 2.5 pg of each reporter plasmid were 
added for transfection. To assure equal transfection efficien- 
cies, samples were devided into two equal parts (400 11 each) 
after transfection and were seeded on two 1 O-cm dishes, one 
of which received hormone (3.3 nM MIB) immediately after 
seeding. Cells were harvested 48 h after transfection for 
preparation of CAT extracts. 
Preparation of extracts and assay for CAT activity was 
performed according to Sambrook et al. (67). Briefly, cells 
were scraped from the culture dish with a rubber policeman, 
washed twice in PBS, and resuspended in 100 ~10.25 M Tris/ 
HCI, pH 7.6. Cells were lysed by two repeated cycles of 
freezing (-80 C) and thawing (4 C), cell detritus was spun 
down at 12,000 rpm for 10 min at 4 C, and the supernatant 
was transferred into a new tube. Fifty microliters of extract 
were incubated at 55 C for 15 min and added to 50 ~1 1 M 
Tris/HCI, pH 7.4, 20 ~1 acetyl coenzyme A (3.5 mg/ml, freshly 
oreoared). and 10 ~1 I’“Clchloramphenicol (0.1 mCi/ml). and 
ihe’ reacion was i&bat& at 37 ‘C for 2 h. One rriilliiter of 
ethyl acetate was added, mixed by vigorous vortexing, and 
centrifuged for 5 min at room temperature. The supematant 
was evaporated under vacuum and reaction products were 
redissolved in 30 ~1 ethyl acetate, 20 ~1 of which were applied 
to the origin of a silica gel TLC plate. Plates were run in 
chloroform/methanol (95/5, vol/vol), dried, and exposed to Fuji 
X-ray films for 12 h. The spots corresponding to the monoac- 
etylated forms of chloramphenicol were measured with a thin- 
layer scanner, and the total amount of [“Clacetyl&Warn- 
phenicol was calculated from the area under the resulting 
peak. 
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